Posted by Michael Wonder on 11 Jul 2023
Pfizer's Cibinqo affordable at $77/month with reimbursement for severe atopic dermatitis
11 July 2023 - A Korean doctor expressed excitement that patients suffering from severe atopic dermatitis will be able to use Pfizer's Cibinqo with reduced financial burden thanks to the recent reimbursement.
Cibinqo is a Janus kinase 1 (JAK1) inhibitor that was approved by the Ministry of Food and Drug Safety in November 2021 and received reimbursement on Monday last week.
